OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
OS Therapies' subsidiary OS Animal Health published peer-reviewed Phase 2 data showing OST-HER2 combined with palliative radiation significantly improved survival in dogs with osteosarcoma. Treated dogs achieved a 20% survival rate at two years compared to 1% in the control group, with median overall survival extending to 159 days from 124 days. Management intends to meet with the USDA in Q3 2026 to align on a regulatory path for conditional approval, while reiterating plans to distribute OS Animal Health shares to OS Therapies shareholders. The subsidiary is also initiating a Regulation Crowdfunding campaign in Q3 to expand its shareholder base to meet U.S.
Key figures
- P value 2yr
- 0.00995
- Control arm n
- 83
- Treatment arm n
- 15
- Survival 2yr control pct
- 1%
- Dogs diagnosed per year us
- 15000
- Survival 2yr treatment pct
- 20%
- Median survival control days
- 124
- Median survival treatment days
- 159
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.